4. In Schedule 1 to the principal Order (which specifies substances which, if included in medicinal products, make those products prescription only medicines, and exemptions from the restrictions on the sale and supply of prescription only medicines)—
(a)in relation to the substance Azelastine Hydrochloride, in column 3, after “seasonal allergic rhinitis”, there is inserted “or perennial allergic rhinitis”, and for “12 years” there is substituted “5 years”;
(b)in relation to the substance Domperidone, there are inserted the following entries—
in column 3—
“For the relief of post-prandial symptoms of excessive fullness, nausea, epigastric bloating and belching, occasionally accompanied by epigastric discomfort and heartburn”;
in column 4—
“10mg of Domperidone (MD)
40mg of Domperidone (MDD)”; and
in column 5—
“Container or package containing not more than 200mg of Domperidone”;
(c)in relation to the substance Domperidone Maleate(1), in column 5, for “100mg” there is substituted “200mg”;
(d)in relation to the substance Ibuprofen(2), in column 5, for “100g” there is substituted “50g”;
(e)in relation to the substance Lodoxamide Trometamol—
(i)in column 2, there is inserted “equivalent of 0.1 per cent Lodoxamide”; and
(ii)in column 3, there is inserted “For the treatment of ocular signs and symptoms of allergic conjunctivitis, in adults and in children aged 4 years and over”;
(f)in relation to the substance Paracetamol(3)—
(i)in column 2, in the entry numbered “(1)”, for “120mg” there is substituted “250mg”;
(ii)in column 3, in the entry numbered “(1)”, there is inserted after “capsules”, “wholly or mainly”; and
(iii)in column 3, in the entry numbered “(2)”, there is inserted after “capsules”, “wholly or mainly”;
(g)in relation to the substance Triamcinolone Acetonide, the entries in columns 2, 3 and 5 are each numbered “(1)”, and, after those entries, there are inserted the following entries—
in column 3—
“(2) In the form of a non-pressurised nasal spray, for the treatment of symptoms of seasonal allergic rhinitis in persons aged 18 years and over”;
in column 4—
“(2) 110mcg per nostril (MD)
110mcg per nostril (MDD)
For a maximum period of 3 months”; and
in column 5—
“(2) Container or package containing not more than 3.575mg of Triamcinolone Acetonide”; and
(h)there is inserted in column 1, at the appropriate place in the alphabetical order of the entries in that column, each of the following substances—
“Cabergoline”
“Cefprozil”
“Indapamide”
“Lansoprazole”
“Lercanidipine Hydrochloride”
“Meloxicam”
“Pantoprazole Sodium”
“Penciclovir”
“Tamsulosin Hydrochloride”
“Ticlopidine Hydrochloride”
“Tiludronate Disodium”
“Toremifene”.